Corium to Report Third Quarter Fiscal Year 2016 Financial Results on Thursday, August 4, 2016
MENLO PARK, Calif., July 28, 2016 (GLOBE NEWSWIRE) -- Corium International, Inc. (NASDAQ:CORI) today announced that it will report financial results for the third fiscal quarter ended June 30, 2016 on Thursday, August 4, 2016 after the close of the U.S. financial markets. Corium will host a conference call and live audio webcast at 5:00 p.m. Eastern time, 2:00 p.m. Pacific time to discuss its financial results and recently announced clinical and regulatory developments.
Conference Call and Webcast Details
Investors and analysts can access the call toll-free by dialing (844) 831-3024 (United States) or +1 (315) 625-6887 (international). The conference ID# is 56382169. The conference call will also be available via a live audio webcast on the Investors section of Corium’s website at http://ir.coriumgroup.com/events.cfm. Please access the website 10 minutes prior to the start of the call to ensure adequate time for any software downloads that may be necessary. A replay of the conference call will be available for two weeks and may be accessed by visiting Corium’s website.
About Corium
Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's broad experience with advanced transdermal and transmucosal delivery systems. Corium has multiple proprietary programs in preclinical and clinical development, focusing primarily on the treatment of neurological disorders, with lead programs in Alzheimer's disease. Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Teva Pharmaceuticals, Endo Pharmaceuticals and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. The company's late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics that is currently in Phase 3 trials, and additional transdermal products that are being developed with other partners. For further information, please visit www.coriumgroup.com.
Corplex™ and MicroCor® are registered trademarks of Corium International, Inc.
Investor and Media Contacts: BCC Partners Karen L. Bergman kbergman@bccpartners.com (650) 575-1509 Susan Pietropaolo spietropaolo@bccpartners.com (845) 638-6290
© Copyright Globe Newswire. All rights reserved. The information contained in this news report may not be published, broadcast or otherwise distributed without the prior written authority of Globe Newswire.
